These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27039386)

  • 1. A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors.
    Milojkovic Kerklaan B; Slater S; Flynn M; Greystoke A; Witteveen PO; Megui-Roelvink M; de Vos F; Dean E; Reyderman L; Ottesen L; Ranson M; Lolkema MP; Plummer R; Kristeleit R; Evans TR; Schellens JH
    Invest New Drugs; 2016 Jun; 34(3):329-37. PubMed ID: 27039386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies.
    Mita M; Kelly KR; Mita A; Ricart AD; Romero O; Tolcher A; Hook L; Okereke C; Krivelevich I; Rossignol DP; Giles FJ; Rowinsky EK; Takimoto C
    Clin Cancer Res; 2011 Jan; 17(1):193-200. PubMed ID: 21208908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin alpha2 on platelets as a biological marker.
    Semba T; Funahashi Y; Ono N; Yamamoto Y; Sugi NH; Asada M; Yoshimatsu K; Wakabayashi T
    Clin Cancer Res; 2004 Feb; 10(4):1430-8. PubMed ID: 14977846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies.
    Keizer RJ; Funahashi Y; Semba T; Wanders J; Beijnen JH; Schellens JH; Huitema AD
    AAPS J; 2011 Jun; 13(2):230-9. PubMed ID: 21387147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium.
    Funahashi Y; Sugi NH; Semba T; Yamamoto Y; Hamaoka S; Tsukahara-Tamai N; Ozawa Y; Tsuruoka A; Nara K; Takahashi K; Okabe T; Kamata J; Owa T; Ueda N; Haneda T; Yonaga M; Yoshimatsu K; Wakabayashi T
    Cancer Res; 2002 Nov; 62(21):6116-23. PubMed ID: 12414636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors.
    Ueda Y; Shimoyama T; Murakami H; Yamamoto N; Yamada Y; Arioka H; Tamura T
    Cancer Chemother Pharmacol; 2011 May; 67(5):1101-9. PubMed ID: 20676675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The small-molecule protein ligand interface stabiliser E7820 induces differential cell line specific responses of integrin α2 expression.
    Hülskamp MD; Kronenberg D; Stange R
    BMC Cancer; 2021 May; 21(1):571. PubMed ID: 34006252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors.
    Bendell JC; Kurkjian C; Infante JR; Bauer TM; Burris HA; Greco FA; Shih KC; Thompson DS; Lane CM; Finney LH; Jones SF
    Invest New Drugs; 2015 Apr; 33(2):463-71. PubMed ID: 25707361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
    Infante JR; Novello S; Ma WW; Dy GK; Bendell JC; Huff A; Wang Q; Suttle AB; Allen R; Xu CF; Ottesen LH; Burris HA; Adjei AA
    Invest New Drugs; 2013 Aug; 31(4):927-36. PubMed ID: 23179337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors.
    Fujisaka Y; Yamada Y; Yamamoto N; Shimizu T; Fujiwara Y; Yamada K; Tamura T; Watanabe H; Sun YN; Bass MB; Seki M
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):935-43. PubMed ID: 20107802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors.
    Mehnert JM; Edelman G; Stein M; Camisa H; Lager J; Dedieu JF; Ghuysen AF; Sharma J; Liu L; LoRusso PM
    Invest New Drugs; 2018 Feb; 36(1):36-44. PubMed ID: 28417284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.
    de Weger VA; de Jonge M; Langenberg MHG; Schellens JHM; Lolkema M; Varga A; Demers B; Thomas K; Hsu K; Tuffal G; Goodstal S; Macé S; Deutsch E
    Br J Cancer; 2019 Feb; 120(3):286-293. PubMed ID: 30585255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers.
    Roohullah A; Cooper A; Lomax AJ; Aung J; Barge A; Chow L; McHale M; Desai J; Whittle JR; Tran B; de Souza P; Horvath LG
    Invest New Drugs; 2018 Oct; 36(5):886-894. PubMed ID: 29766337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.
    Soria JC; Gan HK; Blagden SP; Plummer R; Arkenau HT; Ranson M; Evans TR; Zalcman G; Bahleda R; Hollebecque A; Lemech C; Dean E; Brown J; Gibson D; Peddareddigari V; Murray S; Nebot N; Mazumdar J; Swartz L; Auger KR; Fleming RA; Singh R; Millward M
    Ann Oncol; 2016 Dec; 27(12):2268-2274. PubMed ID: 27733373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.
    Shapiro GI; Rodon J; Bedell C; Kwak EL; Baselga J; Braña I; Pandya SS; Scheffold C; Laird AD; Nguyen LT; Xu Y; Egile C; Edelman G
    Clin Cancer Res; 2014 Jan; 20(1):233-45. PubMed ID: 24166903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.
    Schöffski P; Aftimos P; Dumez H; Deleporte A; De Block K; Costermans J; Billiet M; Meeus MA; Lee C; Schnell D; Goeldner RG; Awada A
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):99-108. PubMed ID: 26650227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current status of combination therapies of angiogenesis inhibitors: vascular normalization activity of a novel angiogenesis inhibitor E7820].
    Semba T
    Nihon Yakurigaku Zasshi; 2013 Jan; 141(1):4-8. PubMed ID: 23302941
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I trial of pazopanib in patients with advanced cancer.
    Hurwitz HI; Dowlati A; Saini S; Savage S; Suttle AB; Gibson DM; Hodge JP; Merkle EM; Pandite L
    Clin Cancer Res; 2009 Jun; 15(12):4220-7. PubMed ID: 19509175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors.
    Yamada K; Yamamoto N; Yamada Y; Nokihara H; Fujiwara Y; Hirata T; Koizumi F; Nishio K; Koyama N; Tamura T
    Clin Cancer Res; 2011 Apr; 17(8):2528-37. PubMed ID: 21372218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.